- Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor
-
We report the synthesis of rigid spirocyclic systems as conformationally constrained variants of the Ala-Phe-NH2 dipeptide amide C-terminus of the calcitonin gene-related peptide (CGRP). CGRP receptor antagonists containing these moieties displ
- Chaturvedula, Prasad V.,Pin, Sokhom,Tholady, George,Conway, Charlie M.,MacOr, John E.,Dubowchik, Gene M.
-
p. 4719 - 4722
(2012/08/13)
-
- CGRP ANTAGONISTS
-
The present invention relates to novel CGRP antagonists of the general formula (I) in which U, V, X, Y, R1, R2, R3 are defined as described below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, and the hydrates of the salts, particularly the physiologically compatible salts thereof having inorganic or organic acids or bases, pharmaceuticals comprising said compounds, the use thereof, and the method for the production thereof.
- -
-
Page/Page column 29
(2011/08/02)
-
- Novel therapeutic agents for the treatment of migraine
-
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their u
- -
-
Page/Page column 19
(2010/02/14)
-
- CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS
-
The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
- -
-
-